Affordable Access Arrives
The landscape of weight management in India is on the cusp of a significant transformation, with the imminent arrival of generic versions of widely used
weight loss medications. These new entrants are poised to drastically reduce costs, with price reductions estimated between 70% and 90%. This means that monthly treatment costs, previously a substantial financial hurdle, could now be as low as Rs 1,290. This development is a direct result of the expiry of patent protections, allowing domestic pharmaceutical manufacturers to produce bioequivalent versions of the blockbuster drug semaglutide. Previously, the high cost of patented drugs like Wegovy and Saxenda made them inaccessible to a vast majority of individuals struggling with obesity and related health concerns. The introduction of generics promises to democratize access to these effective treatments, potentially impacting public health by aiding in the management of chronic conditions associated with excess weight.
Market Entry and Pricing
Several domestic pharmaceutical companies are stepping into the market with their generic versions of semaglutide, following the expiration of the drug's patent. Natco Pharmaceuticals and Eris Lifesciences are among the first to launch, offering the lowest dose per month at Rs 1,290. Natco will introduce its products, 'Semanat' and 'Semafull,' in 2 mg, 4 mg, and 8 mg dosages. Their multi-dose vials will be priced at Rs 1,290 for the lowest strength and Rs 1,750 for the highest. Additionally, Natco plans to release an easy-to-administer pen device next month, with prices ranging from Rs 4,000 to Rs 4,500 for the different doses. Eris Lifesciences will also launch its product, 'Sundae,' at comparable price points to Natco's. These injectables are slated for availability from Saturday. This competitive pricing strategy directly contrasts with the innovator drug prices, where Novo Nordisk's Ozempic for diabetes typically ranges from Rs 8,800 to Rs 11,175 monthly, and its weight-loss counterpart, Wegovy, costs between Rs 10,850 and Rs 16,400 per month.
Competitive Landscape Evolves
The entry of multiple domestic players is set to reshape the weight loss drug market in India. At least half a dozen companies, including prominent names like Dr Reddy's, Natco Pharma, Eris Lifesciences, Zydus, and Alkem, are launching their semaglutide versions concurrently. Many more, such as Sun Pharma, Lupin, and Mankind, are expected to follow suit in the near future. Industry projections indicate that approximately 43 companies have either secured regulatory approvals or have their generic formulations in development, with widespread introductions anticipated over the coming months. While some analysts had predicted intense price wars, the generics are expected to settle within a relatively narrow price band, all significantly below the original brand's cost. This surge in competition, driven by the availability of affordable generics, is projected to double the sales volume of GLP-1 units within the next three months due to enhanced affordability and increased patient accessibility.
Innovator vs. Generic Advantage
Natco Pharmaceuticals is positioning itself as a first mover, emphasizing the significant cost advantage of its generic semaglutide. The company's vial pricing is nearly 90% cheaper than the innovator's drug. Even for pre-filled pens, which offer convenience and full monthly dosages, prices are expected to be up to 72% lower than the original product. Natco secured approval for its generic semaglutide in both multi-dose vials and pen devices in February 2026. Crucially, Natco is the first to offer semaglutide in a vial dosage form, a format that allows for customized dosing and potentially better cost management for patients. This flexibility contrasts with the innovator's current offering, Wegovy, which is sold as a pre-filled syringe containing four doses for weekly administration. Natco's innovation in dosage forms is expected to enhance patient compliance and overall accessibility to GLP-1 therapies for long-term weight management.
